NervGen Pharma Corp (NGEN) - Cash Flow Conversion Efficiency

Latest as of September 2025: 1.808x

Based on the latest financial reports, NervGen Pharma Corp (NGEN) has a cash flow conversion efficiency ratio of 1.808x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-5.32 Million ≈ $-3.85 Million USD) by net assets (CA$-2.94 Million ≈ $-2.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

NervGen Pharma Corp - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how NervGen Pharma Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NervGen Pharma Corp (NGEN) financial obligations for a breakdown of total debt and financial obligations.

NervGen Pharma Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of NervGen Pharma Corp ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Liton Technology TWO:6175	0.056x
Settlebank Corporation KQ:234340	0.049x
Sprott Focus Trust NASDAQ:FUND	N/A
BK Technologies Inc NYSE MKT:BKTI	0.255x
Relais Group Oyj HE:RELAIS	-0.002x
KC Co. Ltd KO:029460	0.023x
Palladyne AI Corp NASDAQ:PDYN	-0.114x
Rojana Industrial Park Public Company Limited BK:ROJNA	0.089x

Annual Cash Flow Conversion Efficiency for NervGen Pharma Corp (2017–2024)

The table below shows the annual cash flow conversion efficiency of NervGen Pharma Corp from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see NervGen Pharma Corp market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CA$2.58 Million ≈ $1.86 Million	CA$-16.84 Million ≈ $-12.18 Million	-6.536x	-216.26%
2023-12-31	CA$-2.01 Million ≈ $-1.45 Million	CA$-11.30 Million ≈ $-8.17 Million	5.622x	+525.55%
2022-12-31	CA$13.46 Million ≈ $9.74 Million	CA$-17.78 Million ≈ $-12.86 Million	-1.321x	-168.70%
2021-12-31	CA$16.82 Million ≈ $12.17 Million	CA$-8.27 Million ≈ $-5.98 Million	-0.492x	+53.85%
2020-12-31	CA$5.92 Million ≈ $4.28 Million	CA$-6.31 Million ≈ $-4.56 Million	-1.065x	+23.12%
2019-12-31	CA$5.84 Million ≈ $4.23 Million	CA$-8.09 Million ≈ $-5.86 Million	-1.386x	-234.95%
2018-12-31	CA$2.51 Million ≈ $1.82 Million	CA$-1.04 Million ≈ $-752.38K	-0.414x	-100.47%
2017-12-31	CA$-11.81K ≈ $-8.55K	CA$-1.04 Million ≈ $-752.38K	88.045x	--

About NervGen Pharma Corp

V:NGEN Canada Biotechnology

Market Cap

$295.10 Million

CA$407.94 Million CAD

Market Cap Rank

#15024 Global

#448 in Canada

Share Price

CA$5.15

Change (1 day)

+0.00%

52-Week Range

CA$2.79 - CA$8.08

All Time High

CA$8.08